Fig. 3From: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancerHigh serum ADAM12 levels associate with unfavorable outcome in tumors located in the rectum. Serum ADAM12 levels were stratified by primary tumor locationBack to article page